Acinetobacter spp. infection is a global problem in ICUs, causing a variety of infections and presenting a challenge to effective therapy, because it is often a multidrug-resistant organism, that can lead to adverse patient outcomes. In the EPIC II point prevalence study of ICU infection, Acinetobacter spp. accounted for 8.8 % of all ICU organisms, with rates as high as 19 % in Asia and 17 % in Eastern Europe [1] . In one study of Asian ICUs, in patients with nosocomial pneumonia, Acinetobacter spp. infection was the most common cause of VAP, accounting for 36.5 % of all episodes overall, and nearly half of all episodes in Thailand [2] . Most of the clinically relevant ICU infections with this organism come from the Acinetobacter baumannii group of organisms. As the frequency of this infection has been rising, our therapeutic options have remained limited, and carbapenems (excluding ertapenem, which is not active against this organism) have been the drug of choice for these organisms, but are less effective than in the past, as resistance to these agents rises. Consequently, we have been forced to resort to therapies with polymyxins, and combinations of other agents (including sulbactam and tigecycline).
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It is against this backdrop that we welcome the recent publication in Intensive Care Medicine of a multinational, multispecialty consensus statement on the management and prevention of A. baumannii infection in the ICU [3] . The document is well organized and offers evidencegraded recommendations on the laboratory diagnosis of infection, the approach to therapy for established infection, and the methods for infection control that can lead to prevention and mitigation of outbreaks with this organism.
Much of the confusion in managing Acinetobacter spp. infection comes from the limited therapeutic options, and the consensus statement provides useful information. The authors propose that empiric therapy for this organism be provided when an infection develops in an ICU with a high prevalence of this pathogen, or if a patient has been previously colonized. This is consistent with several recent studies. For example, Nseir and colleagues found that occupying an ICU room that previously housed a patient with Acinetobacter infection or colonization raised the likelihood of the subsequent patient in that room acquiring Acinetobacter by an odds ratio of 4.2 [4] . ICU ecology also had an impact on the bacteriology of VAP in another study [5] . In that study, 152 patients had early onset VAP with no classic risk factors for resistance, yet 50.7 % harbored multidrug-resistant pathogens, including 15.8 % with A. baumanii. The authors identified that one risk factor for acquiring these organisms was hospitalization in an ICU with more than a 25 % incidence of multidrug-resistant pathogens. The impact of environmental exposure and environmental contamination is an important consideration in determining the bacteriology of infection and in choosing empiric therapy in the ICU, and the topic of environmental cleaning to prevent Acinetobacter infection is also discussed in the consensus statement.
The statement does suggest that if Acinetobacter is being treated in an ICU with a low rate of resistance, then a carbapenem should be used, generally as a single agent. If however, Acinetobacter resistance is common, then they recommend using a multidrug regimen that includes a polymyxin, and maybe also a carbapenem, sulbactam, and/or tigecycline. The role of combination therapy in Acinetobacter infection is complex, and the authors do not recommend its use in directed therapy, but do acknowledge the benefit of combination regimens for empiric therapy when high rates of resistance are present, or when agents like sulbactam or tigecycline are used. The authors pay particular attention to dosing and pharmacokinetics in recommending specific therapies and the potential benefit of prolonged infusions of carbapenems, sulbactam, and polymyxins. They also consider the potential benefit of adjunctive aerosolized polymyxin in the therapy of highly resistant pathogens, and in patients with a poor response to systemic therapy, but do not consider if this adjunctive therapy should be used routinely. The role of tigecycline in Acinetobacter infection is evolving, and it may be necessary to use higher doses than in the past. The consensus statement recommends a loading dose of 200 mg and a daily dose of 100 mg twice daily for the therapy of nosocomial pneumonia, although this is an unapproved dose. However, the prior failures of tigecycline monotherapy in VAP did involve lower doses, and a recent proof of concept study showed that higher doses are feasible and reasonably well tolerated [6, 7] . However, with multidrug-resistant Acinetobacter, and tigecycline MIC values greater than 2 lg/ml, tigecyclinebased regimens are less effective than colistin-based regimens [8] . Several new therapies for this pathogen are in development, but are not discussed in the consensus statement, One important therapeutic decision that is also unresolved is duration of therapy, and the consensus statement recommends 2 weeks for severe infections such as VAP and severe sepsis, acknowledging that more data are needed in this area.
Prevention of infection and infection control are also an important focus in the consensus statement. The authors recommend contact precautions whenever a patient harbors this organism, and also they recommend activating a high level of alert and awareness whenever a patient has this organism, focusing on cohort isolation, hand hygiene, and environmental decontamination. In the setting of an outbreak, they also recommend the use of surveillance cultures, using weekly rectal and pharyngeal swabs, and tracheal aspirates from intubated patients. The authors point out that in a true epidemic situation, ''it takes a village'', and there must be full cooperation throughout the hospital, from the doctors and nurses, all the way up to the hospital administration.
The current consensus statement is a good step forward. It organizes what we know and provides practical recommendations for current management. Like all good statements of this type, it is evidence graded, so that we know the strength of the current knowledge base and, most importantly, the agenda for future research (Table 1) . 
